Find Reports
Select Report Type
Reimbursement Review
Displaying 1326 - 1350 of 1426
Please scroll or swipe to the right to view the full content.
| Title | Brand Name | Generic Name | Files | Therapeutic Area | Recommendation Type | Status | Submission Date | Recommendation Date Sort ascending | Project Number |
|---|---|---|---|---|---|---|---|---|---|
| CADTH Pharmaceutical Reviews U... | |||||||||
| CADTH Pharmaceutical Reviews U... | |||||||||
| RET fusion-positive non-small ... | RET fusion-positive non-small cell lung cancer | Withdrawn | PH0020-000 | ||||||
| CADTH Pharmaceutical Reviews U... | |||||||||
| CADTH Pharmaceutical Reviews U... | |||||||||
| ferumoxytol | TBC | ferumoxytol | Iron deficiency anemia | Withdrawn | SR0753-000 | ||||
| CADTH Pharmaceutical Reviews U... | |||||||||
| CADTH Pharmaceutical Reviews U... | |||||||||
| Mvasi for Metastatic Colorecta... | Mvasi | Bevacizumab | mCRC NSCLC Biosimilar | N/A | Complete | PC0158-000 | |||
| natalizumab | Tysabri | natalizumab | Multiple Sclerosis, relapsing-remitting | Withdrawn | SR0687-000 | ||||
| apomorphine hydrochloride | Kynmobi | apomorphine hydrochloride | Parkinson’s Disease | Withdrawn | SR0604-000 | ||||
| CADTH Pharmaceutical Reviews U... | |||||||||
| CADTH Pharmaceutical Reviews U... | |||||||||
| CADTH Pharmaceutical Reviews U... | |||||||||
| CADTH Pharmaceutical Reviews U... | |||||||||
| filgotinib | TBC | filgotinib | Arthritis, Rheumatoid | Withdrawn | SR0656-000 | ||||
| CADTH Pharmaceutical Reviews U... | |||||||||
| CADTH Pharmaceutical Reviews U... | |||||||||
| CADTH Pharmaceutical Reviews U... | |||||||||
| CADTH Pharmaceutical Reviews U... | Pending | ||||||||
| Pharmaceutical Reviews Update ... | |||||||||
| dostarlimab | Jemperli | dostarlimab | Endometrial cancer | Active | PC0381-000 | ||||
| zanubrutinib | Brukinsa | zanubrutinib | Relapsed or refractory follicular lymphoma | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0037-000 | |||
| solriamfetol | Sunosi | solriamfetol | Excessive daytime sleepiness (narcolepsy) | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0038-000 | |||
| Pharmaceutical Reviews Update ... |
Health Technology Review
Displaying 601 - 602 of 602
Horizon Scan
Displaying 101 - 110 of 110
Projects in Progress
Displaying 26 - 27 of 27
View All Reports
Displaying 1326 - 1350 of 2138
Please scroll or swipe to the right to view the full content.
Provisional Funding Algorithm
Displaying 76 - 81 of 81